FUJIF - Fujifilm to inject ~$850M investment for CDMO subsidiary

Fujifilm (FUJIY) will invest ~$850M in its core biopharmaceutical contract development and manufacturing organization ((CDMO)), Fujifilm Diosynth Biotechnologies.The investment will go towards increasing manufacturing and development capacity, including a twofold increase in cell culture production for recombinant vaccines, including Covid-19 vaccines, in the U.S.It will also go towards a tenfold increase in gene therapy production and tripling of cell culture capacity, including cGMP capacity for continuous manufacturing, at an existing 5,000L facility in the U.K.The expansions will begin operating by late 2023. Fujifilm will announce additional details on the new and expanded facilities once initial engineering studies conclude.The new investment is part of Fujifilm's efforts to address market demand for biopharmaceuticals. The company has invested $5.5B in Fujifilm Diosynth Biotechnologies since 2011.FUJIY +0.50% pre-market.Press Release

For further details see:

Fujifilm to inject ~$850M investment for CDMO subsidiary